Announcing the SOSV Climate Tech Agenda

Welcome to the agenda for the main stage of the SOSV Climate Tech Summit. The event is virtual, free and will be held on Oct. 25-26, starting at 8 a.m. PDT. Register today. 

The main stage features conversations between the world’s top climate founders and investors across all the major categories of climate tech – from energy to industry and food. The conversations will be moderated by editors and reporters from TechCrunch, Bloomberg, The Economist, MIT Technology Review and more. 

In addition to the sessions below, there will also be a track of more than 20 live breakout sessions led by the top early stage investors, including SOSV (HAX and IndieBio), Khosla Ventures, DCVC, Breakthrough Energy Ventures, Lowercarbon Capital, Energy Impact Partners, Fifty Years, World Fund, Pale Blue Dot, MCJ Collective and more. Their presentations are designed to help founders understand better how these firms make investment decisions. Register today.

The SOSV Climate Tech Summit is designed to convene the emerging climate tech startup and investment ecosystem, which is relatively new and very global. More than 70 new venture climate funds launched in the past year, and hundreds of new climate-focused startups took shape. The summit aims to expand access to information within the ecosystem and deepen the person-to-person connections essential to startup ecosystems. 

Join us at the SOSV Climate Tech Summit and get to know the people, startups and investors building the this vital tech ecosystem.

The Agenda

Watch IndieBio NY’s Spring 2022 Class 04 Demo Day

It was definitely a night to remember! After months of hard work, many came together to celebrate the milestones and accomplishments our Class 04 companies achieved during our Spring 2022 program. The event began with opening remarks from Joan Spivak, Senior Director, Life Sciences for Empire State Development, an organization that we are proud to partner with as we work together to build and strengthen the life science and deep tech ecosystem here in New York and beyond. In addition to hearing about each company’s mission, IBNY’s Program and Partnership Coordinator, Maddy Behr detailed what our unique startup development program offers to each team and ways that industry and professional experts can collaborate with us while Alex Hall-Daniels and Lindsay Atkeson, IBNY’s Business Analysts, discussed upcoming future trends in human and planetary health. After each company shared how they were solving issues across three sectors (Therapeutics, Diagnostics, and Industrial and Agriculture Tech), there was a palpable excitement and energy to help these teams succeed in the room. Below, you can find a detailed list of each company and ways to contact them to learn more.

Interested in applying? We are currently accepting applications for our upcoming IBNY05 Fall 2022 cohort here.

Therapeutics

Diagnostics

Industrial and Agricultural Tech

Sea & Believe developing realistic, flakey plant-based cod

The Spoon article “Sea & Believe is Making Plant-Based Whole Cut ‘Cod’ That Flakes Like Real Fish” reports on the development of a new product for a startup that already sells two alt-fish items, a seaweed burger and seaweed goujons. Growing up in Ireland, Sea & Believe (SOSV IBSF12 2021) founder Jennifer O’Brien discovered the health benefits of eating seaweed to help with her asthma. According to the article, O’Brien and Chief Technology Officer Piyali Chakraborty believe their alt cod filet made from Irish seaweed “will be the first plant-based seafood product to flake just like the real thing.”

The story is also covered in Vegconomist.

Announcing the second annual SOSV Climate Tech 100, including 58 IndieBio alums

Now in its second year, the SOSV Climate Tech 100 is shaping up to be a great showcase for SOSV’s climate tech mission and investing. More than half of the companies on the list—58 to be exact—graduated from IndieBio. 

In the past year, the 100 have doubled in valuation, reaching more than $11 billion, and the amount of capital raised by the same companies also doubled, to reach 3.8 billion. The number of unicorns on the list  jumped from two (Formlabs, GetAround) to five (Perfect Day, NotCo, Upside Foods), and those five represent 10% of the climate unicorn count globally. 

In this post over at SOSV’s website, there is a lot more detail on the Climate Tech 100’s  founders and  investors, as well as the complete list. Also worth noting: the planning of this year’s SOSV Climate Tech Summit (October 25 – 26) is well underway (register now). We look forward to advancing the conversation about the emerging climate tech ecosystem with investors, founders, and leaders.

Stämm Biotech raises $17M in series A for its next-gen, 3D printed bioreactor

TechCrunch” “Stämm Biotech raises $17M for its next-generation, 3D printed bioreactor” reported the series A round was led by Verana Capital and supported by several new and follow-on investors, including SOSV.  According to the article, Buenos Aires-based Stämm Biotech (SOSV IBSF07 2018) uses a 3D printer to create a bioreactor that employs microfluidics. The Stämm device creates a “dense network of microchannels that pass cells through the nutrients and oxygen they need.”

Although still in the early stages of commercialization, the startup says it is “working with one European biopharma company focusing on producing biosimilars” and has five potential new partners in the pipeline, aiming for “pilot scale” in 2022.

SOSV’s Year in Review 2021: Deep tech’s inflection point

In “SOSV 2021: The year in review,” SOSV Managing General Partner Sean O’Sullivan goes over the factors that drove a 40% increase in assets under management and lifted several portfolio companies to unicorn status in what was a “stunning” year for SOSV. 

More important, O’Sullivan argues that the deep tech investing category has hit an inflection point, which is important to SOSV’s deeptech driven missions in human and planetary health. He cites the rapid increase in valuation of the SOSV Climate Tech 100, up 66% since last April to reach $10 billion, and the great progress of SOSV’s companies in the food sector, where SOSV is top-ranked. He cites the following: 

  • In July, NotCo, a 2017 IndieBio grad, raised a $235 million series D led by Tiger Global and reached a reported $1.5 billion valuation. NotCo is a food technology company that originated in Chile and makes plant-based milk and meat replacements.
  • In September, Perfect Day, a 2014 RebelBio company, raised $350 million in a round led by Temasek that pushed the company to a reported $1.5 billion valuation. Perfect Day makes animal-free dairy products.
  • In November, Upside Foods (FKA Memphis Meats), an IndieBio 2015 graduate, opened the world’s first commercial scale production facility, in Emeryville, California, for the production of sustainable, cultured meat.
  • In December, The Every Company (FKA Clara Foods), another IndieBio 2015 graduate, raised $175 million and earlier this year reached an agreement with AB InBev to brew animal free proteins at industrial scale.

Read more.

IndieBio NY Class 3 Demo Day: Ready to make an impact

IndieBio NY Demo Day was a huge success! The 10 graduating startups gave 3-minute presentations on the huge problem they are tackling in human or planetary health, their technical product that solves the problem, and the opportunity for immense impact for good when these startups succeed.

Thank you for all the enormous support to our founders and for believing in the vision that biology is the future.

Congrats to the fantastic startups who participated in IndieBio NY Class 3:

  • Bosque Foods: Whole muscle meat alternatives grown naturally from fungi
  • Ceragen: Probiotics for plants to increase crop yields
  • Helex: Enabling safer gene editing
  • Inso Biosciences: Next-generation sample prep. In solution
  • Kutanios: Defending skin against environmental and aging-related damage
  • Kyomei: Transforming meat protein production with plants
  • Pannex Therapeutics: Developing life-transforming therapies based on blocking Pannexin 1 channels
  • RizLab Health: Bringing blood analysis to patients’ fingertips
  • Tômtex: Designing the future of sustainable biomaterial
  • Upright: Plant-based goods to nourish the world

Did you miss it? Do you want to watch again? Review the short presentations from each IndieBio NY Class 3 at the event archive here or enjoy the event recording below.

Bosque Foods: Whole-Cut Meat Substitutes From Fungi

Consumers looking for meat alternatives love their nuggs and burgers, but no company has recreated the experience of a chicken cutlet or scallop in taste and texture. Bosque Foods leverages the power of fungi to create whole-cut meats to satisfy any vegan, vegetarian, or flexitarian using clean ingredients and minimal processing. We spoke with CEO Isabella Iglesias-Musachio about her whole-cut alternative and the future of food.

Watch Bosque Foods present at IndieBio NY Class 3 Demo Day

“I think that we’re gonna have a lot of different types of foods that are coming to market in the next 5 to 10 years that are really going to change food and our culinary traditions.”

How did you learn about the problems around our current food systems?

I was born in New York, and I ended up going to school for sustainable agriculture and sustainable development. It was while studying about agriculture that I learned about animal farming, and all of the disastrous side effects of our mass agricultural system and how that links to issues of climate change. It’s where I learned about largely the carbon footprint of the animal agriculture industry, as well as the inhumane practices in terms of raising livestock. 

That’s what made me decide to become a vegetarian at 16. That’s also where I got really interested in food and food technology. And, yeah, that’s what sparked my interest in sustainability, in different types of food products, and why I would later one day start Bosque Foods. Kinoko Labs.

What led you to found Bosque Foods?

I got my degree, and then I ended up working actually in different NGOs and nonprofits, with sustainable agriculture as well. But eventually, I started working in the tech industry. 

I got recruited by a French corporation, so moved to Europe, and helped to open multiple Tech Shop startups throughout France. After that, I went on to work for another startup in Berlin, in Germany called InFarm. So over the course of my career, I worked in pretty much only startups after, you know, working in just nonprofits and NGOs. I found from that experience that I really love the pace of startups. I also felt like you could tackle really ambitious problems and really big humanitarian issues with the startup and actually succeed. 

So I’m very used to working in startups. I’m very familiar with building them and you know, also have a lot of experience in working in different stages of the startup, so for me, it was kind of like a natural step to start my own startup.

What is missing from plant-based products available on grocery shelves today?

In comparison to plant based meat alternatives, what’s on the market today is mostly burgers and sausages and nuggets and all these de-texturized protein products. And at the end of the day, what consumers want are processed products that are minimally processed, healthier, nutrient dense, and that they have more variety and texture. 

It’s very hard to create a whole textured product with just a pea protein isolate, it has to be extruded, which means it has to become ultra-processed with a label that’s, you know, 20, 40 ingredients long. Consumers look at that, and they don’t want to eat that every day or they feel they don’t want to feel guilty about eating that every single day. 

So what we’re able to create are products that are minimally processed, nutrient dense, thereby healthier, while also having a meat like texture, naturally. Mycelium has an inherent fiber structure and network that allows us to leverage that, you know, perfectly for the use and creating whole cuts.

How do mycelium create whole-cut meat substitutes?

Mycelium is the vegetative root network of a fungi. An everyday example of where you would find mycelium is actually underground–if you were to go in the forest and you see a mushroom for example, popping up, then you what you can actually understand is that mycelium is all the root network underneath, that connects to different mushrooms and also to different plants 

But there’s also ways that you can cultivate mycelium not using soil, you can cultivate it the way that we do, which is essentially like tricking the mycelium into thinking that it’s in the ground, or that it’s in a tree trunk, for example. 

And so we mimic the environment of soil or we mimic the environment of a tree trunk so that the mycelium grows within our very pure and clean environment. And in that way, we’re able to cultivate pure mycelium. We then harvest that and we use that as the main ingredient in our meat alternatives.

What is your dream for Bosque Foods’ products?

By creating products that consumers can make a one-to-one switch for and that they that they love and that they adopt, we’ll be able to lessen their reliance on animal based products. So the idea is essentially that the more we can convince people to eat non-animal-based products instead of their typical animal meat. 

For me, I hope that people will just really love the product and love the way it tastes and be able to use it in the way that they would typically use regular animal meat. I think the ideal is that a consumer can basically have a one-to-one switch for their animal product with our product. So anytime that a normal person, a consumer, would want to have a barbecue or, you know, make themselves whatever their favorite meat dish is, they could instead use the product that we create.

How will our food landscape change in the next few years?

We’re really at this inflection point, I think in history. There’s the Industrial Revolution, and we’re now in this other type of revolution, where we can create food in extremely different ways, that are not only very different, but also healthier and more sustainable. 

We’re at, I think, one of the most interesting points in history from a technology perspective, because it’s really right now that the future of food is being created. 

Ideally, we’re creating a product that people can use today, that they’re going to be able to, you know, not change their entire culinary tradition, but just incorporate what we’re building. But at the same time, I think that we’re gonna have a lot of different types of foods that are coming to market in the next 5 to 10 years that are really going to change food and our culinary traditions.

Helex Bio: Building the GPS for Gene Therapies

CRISPR may be a Nobel Prize winning discovery, but its translation into a therapeutic use raises many questions on safety, edit specificity and their consequences. In CRISPR, a short RNA (guide RNA) navigates the Cas enzyme to make the edit in the right place, and this gRNA plays a critical role in safety. Helex’s novel platform is advancing the design, in vitro validation and manufacturing of therapy grade synthetic gRNAs to accelerate drug developers to enhance safety of their therapies. 

Watch Helex present at IndieBio NY Class 3 Demo Day

We spoke with CEO Poulami Chaudhuri, Ph.D., about a future without genetic disease. 

What is the mission of Helex Bio?

The mission of Helex is to drive synthetic guide RNA driven therapeutics to solve for rare genetic conditions by partnering with drug developers. Safety is one of the biggest challenges in translating promising technologies like CRISPR into workable therapies, and we want to contribute to making gene editing safer, ultimately accelerating these therapies to market. 

What inspired you to found Helex? 

I have experienced firsthand the advancement of science from a genetics perspective to be able to accurately read the genetic code and understand its consequences on human life. It is extremely inspiring to see how we have moved from accurately reading the code to holding the potential to actually solve for these conditions. 

As a new mother, I wanted to apply my extensive experience in the space of genetics, molecular biology and bioinformatics to contribute to alleviating the pain undergone by those who suffer from rare genetic conditions that until now have had no real solutions. 

What is the key to developing safer CRISPR-based gene therapies?

To develop safer CRISPR-based gene therapies, it is critical to deepen our understanding of the core cellular and tissue mechanisms, and thus to understand the impact of making a DNA edit on all aspects of these cell and tissue mechanics. 

While science has come a long way, the specificity of edits and its consequences of off-targets needs to be better understood and defined. The human body is complex, and every edit has a unique and significant impact. This impact has to be uncovered at many dimensions to make these therapies safer. 

How does Helex create safer therapies?

Helex is the GPS for gene editing. We look at the entire design of guide RNA from a three dimensional, four dimensional perspective. We have an AI-based modular platform that makes the most precise guide RNAs which are gene, cell & tissue specific. 

Today one of the biggest challenges for performing gene therapies within the body, or in vivo, is the unintended tissue effects. So while the entire field is working towards vector innovation and development, at Helex, we are designing tissue-specific guide RNAs. These tissue-specific guide RNAs act as an extra layer of safety even when there is a leaky expression by the vector.

What does it mean to design guide RNA from a 3D or 4D perspective?

At Helex, we are advancing this science using the principles of epigenetics which states that structure defines function. Every cell functions differently, and the epigenetics vary between cell types. 

Our platform informs guide RNA design keeping in mind these core principles, and are catered to every cell/ tissue type to make them extremely specific. This is especially pertinent when we talk about in-vivo or inside the body editing. 

In addition, we do a very detailed safety characterisation of the edits at the genotypic, phenotypic level, and keeping in mind the impact on the target gene and all other genes associated with it. This is the 3D/ 4D holistic approach that we take. 

How will you work with other cell & gene therapy companies? 

We intend to be a lead guide RNA optimizing partner for drug developers, where we custom design gRNAs using our platform and based on their therapeutic modality. We will validate  and characterize these gRNAs as drug substances and ultimately synthesize them for the drug developers. 

What keeps you motivated to bring your product to market? 

Complete strangers reach out to us on social media platforms like LinkedIn and give us encouragement because they have a loved one that is suffering from one of these conditions, and express their hope for these therapies to see the light of the day. We feel a sense of purpose and inspiration despite the surmounting challenges.

RizLab Health: Bringing Instant Blood Analysis to Patients’ Fingertips

RizLab Health is addressing the pandemic of antimicrobial resistance and helping clinicians by pinpointing the source of infection (and thus preventing inappropriate antibiotic prescriptions) with their point-of-care device, the CytoTracker. The CytoTracker differentiates bacterial from viral infection profiles within minutes. A 200-person clinical study demonstrated the CytoTracker beats the specificity of current testing methods, making it the most affordable, portable, and accurate blood analyzer, with additional applications on the horizon.

Watch Rizlab Health present at IndieBio NY Class 3 Demo Day

We spoke with RizLab CEO Mehdi Javanmard, Ph.D., about his portable blood analyzer and what science tells us can really be tested using a drop of blood.

What work prepared you for making small, portable lab devices?

I started out working at the Stanford Linear Accelerator Center, where we were working on making accelerators that are normally several miles long, that can make electrons travel at the speed of light, down to the size of a shoe box. 

The lab that I did my doctoral studies in Stanford, the Stanford Genome Technology Center, was was home to numerous spin off companies, and numerous innovative discoveries in the space of biotechnology, namely, the DNA microarray, and also many important large biotech companies spun out of that lab, including Illumina. 

I was working on a project that involved taking large scale labs, and shrinking it down to the size of a chip.

How does the name RizLab relate to a portable white blood cell lab?

So as an electrical engineer, I was always fascinated with miniaturization. of labs. I did my doctoral studies on making labs for detecting cells, microbes, and mammalian cells, shrinking them, making them really small. I continued further developing these technologies over the years in an academic setting. 

When the technology got to a point where I felt it was robust enough to actually be used in the hands of patients, that’s when we decided to spin off a company. 

The word riz in Farsi, which is the language spoken in Iran, which is the land that my parents immigrated from over 40 years ago, means very tiny. And since I’ve dedicated my whole career to making very tiny labs, we decided to name the company, Riz Lab.

How does the first product from RizLab Health, the Cytotracker, measure blood components?

The Cytotracker is a fully electronic device that has a really small reader thatt fits in the palm of your hand, and a tiny microchip that plugs in, which is disposable. And the disposable test strip has inside it a microfluidic channel with sensors. 

What that means is that there’s a tiny channel that is thinner than the diameter of one human hair, where cells pass over micro electronic sensors in a single file line, similar to how airport passengers walk through a security line in a single file line, walking past a facial scanner.

Can you really do this with only a drop of blood?

The first question that investors and scientists alike ask us is: can you really do this with only a drop of blood? The answer is that there are many things that you can do with only a drop of blood, many different analytes [you can measure] as long as you’re focused, and you’re targeting the right set of analytes so that the concentrations are not widely different. 

What’s difficult though, with a single drop of blood is, trying to tackle a wide range of analytes, trying to do 200 things at once that have, you know, over six orders of magnitude, right? That’s one million times difference in concentration—that’s very hard. 

Focusing on molecules and analytes that are fewer in number while using a more targeted approach—that’s something that is completely feasible.

What insight allowed you to create the Cytotracker?

Quantifying white blood cells in a drop of blood is challenging, because it’s similar to a haystack that has hundreds of millions of straws of hay with a few thousand needles, and you’re trying to find out exactly how many needles are in that haystack. 

What we did was come up with a novel way to make the hay straws invisible, electrically, and only be able to detect and quantify the needles.

How does your recent clinical trial support the mission of RizLab Health?

RizLab’s mission is to democratize diagnostic technology by making it extremely portable and extremely affordable. 

Results of our recent 200-person study mean for RizLab is that it proves the speed, the portability, and also the accuracy of our device, showing that this is a commercially viable option that has the potential to make it all the way to regulatory clearance. 

I hope to see in the future that one day everybody will have access to tiny labs, so that they can continuously monitor their health and so that diseases can be diagnosed within minutes, not days.

Pannex Therapeutics: Anti-Addictive Painkillers to Save Lives

Cells send “danger” signals to alert the immune system when they are under attack. Under the wrong conditions, these signals can lead to chronic inflammation and many downstream pathologies, including chronic pain. Pannex Therapeutics stops the production of one of these danger signals—extracellular ATP—by blocking a protein called the Pannexin 1 channel, which sends ATP outside of the cell. This novel mode of action will help Pannex CEO David Bravo, Ph.D., as he develops drugs to treat chronic pain and other diseases caused by incorrect danger signaling.

Watch Pannex Therapeutics present at IndieBio NY Class 3 Demo Day

We spoke to David about building Pannex Therapeutics.

What inspired you to help those suffering from chronic pain?

When I was a clinician, I had to support a lot of people in pain. And it was super frustrating to see how they struggled with that. And the drugs appear not to work and it’s like, what’s going on here? This is a human burden, and nobody seems to care. 

And also my mother in law, she suffers chronic pain, everyday. She started on opioids and we almost lost her. There’s gotta be another thing to do, and there was nothing. So I took action.

I’m David Bravo, I’m the CEO of Pannex Therapeutics. I’m from Chile, although I was born in Brazil, and by training, I’m a physical therapist and a PhD in neuroscience. From that point from the PhD, I started with this crazy idea of: what if I have one molecule that can block many diseases? And I found that target in the Pannexin 1 channel.

What are the biggest problems around chronic pain?

Chronic pain is a high demand medical need because it affects 100 million Americans today. And it costs billions of dollars to the healthcare system. And the best choice that the patients have, the opioids, are killing one American every 15 minutes. And the other drugs, the non opioids, fail in 50% of the cases in relieving pain.

We are trying to change the opinion that there is no solution for chronic pain. This is a common opinion among physicians, that chronic pain is a too-complex phenomenon, so it’s really almost impossible to solve it. But we believe we can do that—and it’s not being pretentious, because science backs this up. We believe that we will bring a definite solution.

What is the mission at Pannex Therapeutics?

The company mission at Pannex is to become the first and only Pannexin 1 channel company, and from that to help mankind to solve many problems in different therapeutic areas.

The other opinion we are trying to change here is that you can treat many diseases by targeting just one target. This is why we’re called Pannex Therapeutics. 

We believe (and our investors, too) that if we target Pannexin, we can go for chronic pain, which I discovered during my PhD, but also go on to pursue and solve and prevent opioid addiction, autism, epilepsy and your inflammation, and other indications. 

There’s tons of data that supports these ideas. And we’re trying to replicate those with our molecules that are selective to the channel. 

What is your unique therapeutic solution for chronic pain? 

Our solution for chronic pain is called PNX3. It’s a molecule that is selective and potent to block specifically the Pannexin1 channel.

We found that PNX3 decreases chronic musculoskeletal chronic pain in rat models at the same level of gabapentin, which is the main competitor on the market, but with 10 times less dose, which means less side effects and less toxicity. 

Also, we found that PNX3 is able to decrease ATP release from brain cells. The Pannexin 1 channel mostly secretes or releases ATP, and we were able to decrease that by 97%, so we have a clear mechanism of action. 

We further discovered that PNX3 crosses the membrane to go directly from the blood to the brain—and it is safe for the brain, because we make experiments in which we put together brain cells and the drug for 24 hours and 100% of the brain cells survived.

How will you get your therapeutic compounds into patients’ hands?

We are narrowing down our selection in order to get to our final candidate. We will look for an easy and quick way to pass through the FDA approval; with that, we will start our safety studies in healthy humans for the phase one clinical trial. 

After that, we’ll go to phase two clinical trials in small groups of people in pain, for example. At that point, we will work in parallel on other indications in humans, probably migraine, epilepsy and, of course, opioid addiction, with the molecules that have been already approved by the FDA to be tested in humans. Then the next one, we go to bigger multi-center studies into phase three clinical trials. 

We believe, as a company, that we can provide this package of technology to the pharmaceutical companies that have the resources and experience to go for it and go to the market. 

Upside Foods and others await FDA approval to produce cultured meat

Photo: Upside Foods

The Bloomberg article “Ready to eat some lab-grown meat? The FDA will soon decide,” reports “the science experiment” that is lab-grown meat “could soon reach your supermarket.” The meat it refers to is grown by Upside Foods (SOSV IBSF02 2015), a startup founded by cardiologist Uma Valeti which recently opened a 53,000-square foot culture-meat production facility in Berkeley ahead of official approvals to sell the product. The article says Upside is currently awaiting FDA regulatory requirements and approval to sell and ship cruelty-free meat, which will likely be chicken nuggets and chicken breasts. 

Chase Purdy, the author of Billion Dollar Burger: Inside Big Tech’s Race for the Future of Food, is quoted about recent developments in the approval process: “There’s been this haggling over the regulatory framework, but these are signs that the agencies are really close.”

AlgiKnit moves its eco-conscious materials production to NC for next stage of growth

Vegconomist reports “Kelp Yarn to Be Produced at Scale as AlgiKnit Opens North Carolina Hub.” The article says AlgiKnit (SOSV RebelBio 05) “aims to cut the fashion industry’s carbon emissions in half” with its eco-conscious biomaterials created from kelp. The company’s new facility in Triangle Park, NC, will house R&D, business, and manufacturing as it prepares to commercialize, scale production, and accelerate growth.

Regarding AlgiKnit’s choice for their new location, co-founder and COO Aleksandra Gosiewski says, “North Carolina’s Research Triangle area is becoming a hub for big tech and life sciences, and we look forward to collaborating with other companies focused on scientific innovation and disruption. We’re also excited for the opportunity to tap into the deep and diverse pool of talent and knowledge in the area to strengthen our scientific and engineering divisions.”

Announcing IndieBio NY Class 3 Demo Day

IndieBio is proud to announce its Demo Day for New York Class 3, taking place on January 27, 2022, with activities scheduled from 12:00pm-1:00pm.

Reserve your tickets here.

IndieBio is the world’s leading biotech startup development program, which supports startups tackling the biggest problems facing human and planetary health. Startups develop scientific projects into products that will transform our food, therapeutics, biomaterials, and diagnostics industries–and more.

IndieBio Demo Day is the opportunity to celebrate with these startup founders, as they highlight the milestones made during the IndieBio program. We welcome you to IndieBio NY Class 3 Demo Day to meet and applaud the deeply mission-driven teams.

The program will feature CEOs from around the world, using biotechnology to solve the biggest problems facing human and planetary health. Get a sneak peak of the startups that will be presenting here.

Upside Foods CEO Uma Valeti on the vegan-friendly benefits of cultured meat

Fortune’s article “Can lab-based meat be vegan?” explores the rapidly evolving industry of cultured proteins and what implications it may have for those who choose a vegan diet. Using Upside Foods (IBSF02 2015) as an example, the article points out how the most common reasons for eating vegan—sustainability, reducing animal cruelty, conserving natural resources—will be called into question by the developing cultured meat economy.

About the inevitable debate, Upside Foods founder and CEO Dr. Uma Valeti says, “We can reduce logistics enormously because we don’t have feed [lots]. We don’t have a slaughterhouse. We don’t have the safety issues that come with having herds of animals intensely confined. But in order to get to scale, we need to have public-private partnerships and continued investment in the field. I have enormous optimism that this is an opportunity not to miss for any stakeholder who cares about impact food and economic opportunity.”

Meat the Future: Behind the Scenes of the Next Agricultural Revolution – December 7

Join SOSV and IndieBio for a panel discussion about the forthcoming “Meat the Future” documentary. This virtual event on December 7, 5:30-6:30 pm PT, is free and open to the public. Register on Hopin.

Told over the span of five years (2016 – 2021), the award-winning documentary Meat the Future chronicles the birth and acceleration of the cultivated meat revolution through the journey of Mayo Clinic-trained cardiologist Dr. Uma Valeti, the co-founder and CEO of Upside Foods (previously Memphis Meats). 

Tune in for a live conversation with Uma Valeti and Meat the Future Director Liz Marshall. Joining them will be Po Bronson, Managing Director of SOSV’s IndieBio, the startup program where Upside Foods produced the first ever cultured meatball in 2016. The panel will be moderated by journalist and author Amanda Little, who is in the film and writes about the environment, agriculture, and innovation. 

The group will discuss the significance of the film, the rapidly evolving cultured-meat industry, and a world where real meat is produced sustainably without the need to breed, raise, and slaughter animals. 

This event is a co-production of SOSV IndieBio and The Redford Center.

Deep Tech NYC Meetup with SOSV’s HAX and IndieBio on Nov. 17

Deep Tech NYC

Join Venture Capital firm SOSV’s deep-tech programs IndieBio and HAX, and tech networking app Supermomos, for drinks and networking.

Come enjoy drinks with deep-tech VC’s, founders, engineers, scientists, and ecosystem partners. If you’re interested in starting a company or already a founder, if you work at a tech company or are looking for a job at a deep tech startup, you’re encouraged to attend and connect! Register here.

Where: The Crooked Knife, 232 West 14th Street, New York, NY

Upside Foods new commercial facility will scale production—and give tours

Fast Company reports on the grand opening of Upside Foods’ (formerly Memphis Meats) (IBSF02 2015) new 53,000-square-foot food production facility in Emeryville, CA.  “Take a look inside this shiny, industrial ‘cultivated meat’ factory of the future” describes the company’s first commercial space for producing meat—chicken, beef, duck, and other meat—from cells grown inside bioreactors. By building the factory in the middle of a bustling neighborhood and designing it to welcome visitors for tours starting in January, Upside Foods’ CEO Dr. Uma Valeti aims to demystify cultured meats and encourage the public to embrace the concept. 

Valeti said, “What’s happened in the last five years is unlike anything that’s ever happened in the food industry. Now we know there’s nearly 100 companies across the world, in nearly every meat-producing and meat-consuming country, trying to do cultivated meat. And that type of acceleration has never happened in food, especially for a completely new space.”

To see video of the grand opening, click here.

Aanika Bio founder to appear in Hulu’s “The Next Thing You Eat”

From lab-grown fish to burger flipping robots, Hulu’s new six-episode docu-series “The Next Thing You Eat” will explore the changes in what we eat. To help advance that discussion, co-founder and CSO Ellen Jorgensen of Aanika Biosciences (SOSV RebelBio) joins an episode to explain how they use microbes to trace and authenticate products in the supply chain. The show premieres on October 21, but you can see the trailer here (Jorgensen appears at 1:57).

Today, we welcome our third cohort of world-changing biotech founders to IndieBio NY!

Germs, Interrupted: Disinfection Innovation Goes Global

A New York-based startup is about to commercialize the first true innovation in disinfection since Louis Pasteur. The startup, Halomine Inc, was founded by Mingyu Qiao and Ted Eveleth, and their first product, HaloFilm™, extends the lifetime of bleach on surfaces from minutes to weeks. At the start of the pandemic, we at IndieBio were really happy to welcome them to our inaugural IndieBio New York cohort; now that they are on the verge of commercializing, we’re even more pleased to support a company that will have huge impacts on human health.

Disinfection innovation is now going global: Halomine recently announced a strategic alliance with Diversey, a leading global provider of hygiene, infection prevention, and cleaning solutions, who will adopt HaloFilm™ technology for institutional and food and beverage markets.

No doubt, this partnership offers a significant opportunity for both Halomine and Diversey: the global surface disinfectant market size was valued at $4.54B in 2020. But the bigger opportunity is the improved human health this partnership represents: HaloFilm’s efficacy against drug-resistant fungi such as Candida auris means this technology can prevent deadly hospital outbreaks.

HaloFilm™ also extends surface disinfection against bacteria and viruses, including SARS-CoV-2. When the Halomine team pitched to IndieBio New York, the COVID-19 pandemic was only beginning, and the team saw a benefit for a long-acting antiviral disinfectant (data hadn’t yet shown that surface transmission is relatively minimal). SOSV invested in many companies battling the pandemic, including Halomine, but Halomine’s technology was also a long-term investment with applications in many sectors.

What sectors? Think of food preparation: industrial kitchens and food processing premises can be sources of foodborne illness. Conveyor belts can be coated with biofilms, hard-to-eradicate bacterial growth, where pathogens like Listeria monocytogenes lurk. Technologies that kill pathogens on contact will prohibit biofilm growth, preventing some estimated 48 million cases of foodborne illness in the U.S. each year. Given that the food processing and handling sector is predicted to exceed $4 trillion by 2024, this technology offers both the chance to improve human health and make significant revenues.

Innovating the disinfection process

The process of disinfection hasn’t changed in 150 years. Why should it? Bleach is a very efficient disinfectant. But consider that 15 minutes after cleaning a surface with bleach, the bleach disappears, and a surface can be recolonized by nearby microorganisms. Now ask yourself: how often are surfaces cleaned with disinfectants? 

HaloFilm™ is a simple spray that is applied before any bleach-based cleaning solution. This creates a thin-layer film that holds bleach molecules close to the surface, ready to attack any microbes that land in the crevices and valleys that constitute smooth surfaces at a microscopic level. The film is harmless to human touch (“as safe as the water in a swimming pool,” as Eveleth likes to say), and the film can be “recharged” with fresh bleach applications to maintain disinfection.

The New York Story

Most of the Candida auris cases in the United States have occurred in New York, which may be why the solution was New York-based as well. Ted Eveleth, CEO of Halomine, joined the company in 2019 with this antifungal application in mind. Then came COVID19. 

Eveleth and co-founder & CTO Mingyu Qiao, Ph.D., met in Ithaca, NY, where Qiao worked on the technology at Cornell University. They licensed the technology and joined the first IndieBio NY program in May 2020 at the beginning of the U.S. COVID19 outbreak. Halomine immediately pivoted to working on coronaviruses, and the IndieBio team celebrated with Halomine when HaloFilm™ was shown to inactivate SARS-CoV-2 using the rigorous CDC rapid surface test for COVID. 

The key connection between Halomine and Diversey was made during the IndieBio NY program. Qiao, encouraged by the IndieBio team to make numerous cold calls, reached out via LinkedIn to the CTO at Diversey pitching Halomine’s latest antiviral data—and the rest, as they say, is history.      

From Local to Global

Controlling infectious disease is a global problem, of course, which is why this partnership is a boon for human health. Partnering with a worldwide company like Diversey means that Halomine will be able to see their technology applied around the world for many uses. The company has specialties in healthcare, facility management, food & beverage, hospitality, and retail spaces, allowing HaloFilm™ to move quickly into the markets where it is most needed.

We are excited to see this technology accelerated into its needed applications. Congratulations to Halomine and Diversey on your partnership!

SOSV, the global venture firm, just closed a $100 million fund to back its maturing startups

Sean O’Sullivan, the founder of the global venture outfit SOSV, has slowly but steadily built up a sizable operation over the years.

SOSV started off as a family office, investing the capital of O’Sullivan after he co-founded two companies, including MapInfo, an outfit that went public in 1994 before Pitney Bowes acquired it years later, in 2007. The seed-stage investing outfit has since raised three more funds, including a $277 million early-stage fund that it closed in 2019 and is actively investing from right now.

Now, to complement those funds, the organization has raised $100 million for what it’s calling a “select fund” that’s meant to help SOSV maintain its pro rata stake in some of its breakaway portfolio companies.

The New Biotech

Explore the “New Biotech” with the IndieBio team and learn how we can re-imagine, re-materialize, and rebuild the world together.

SOSV Takes On Y Combinator With A Pure Biotech Accelerator

As a traditional natural science, biologists used microscopes to better understand the human body. “A lot of therapeutics have been observations through nature. Like finding a tree bark and turning that into a drug,” CSO and Partner, Jun Axup explained. Yet as we continue to integrate technology into biology, we’re able to redesign and reengineer our very nature.

“Over the last 70 years, we have really perfected the ability to read, write, copy, cut, and paste DNA,” Axup continued. “Pretty much everything we see and use around us has some relation to biology, and can be potentially improved upon using biotechnology.”

Five years ago, in the early days of biohacking, IndieBio started as an experiment out of SOSV Accelerator, to give scientists a chance to become entrepreneurs. “We think that PhDs and other scientists can actually take the science that they’ve been working on and build a company,” Axup said.

In the early stages of IndieBio we invested in food, agriculture, medical devices, biopharma, neurotech, computational bio, industrial bio, and regenerative medicine. “We took the risk that nobody else would take,” Head of Investor Relations, Maya Lockwood said.

In some ways IndieBio is a petri dish, where we spread startups out into the bio-atmosphere. Some will survive and some will not. From watching many startup’s life cycles we’ve learned some important variables. What works in the market, who’s paying for what kind of technology, and what kind of team culture makes a successful company?

We’re now at an inflection point, where the pandemic has rapidly exposed our system’s vulnerabilities in our healthcare and food supply systems. While at the same time the technologies of the “future” don’t seem so far away.

For the last couple of decades humans have engineered digital systems to manipulate biology to scale sustainable solutions, launching the synthetic biology revolution. “We’re seeing a lot of this convergence in the neurotech space,” CTO, Pae Wu said. “New materials and digital systems are being able to interface really well and elegantly with biology, neurons, and muscles.”

Enter 2020, and we’ve experienced the reality of natural disasters and diseases threatening our lives. Through this we have realized, to maintain our human health we must also maintain our planet’s. “The two are hand in hand,” Axup said, “and in some ways, planetary health is more important. If we don’t have a planet, then our individual health doesn’t really matter.”

Here at IndieBio, we kept these lessons in mind when we invested in solutions for food supply, climate change, agriculture, medicine, and diagnostics.

As people continue to spearhead the development of biotechnology, we call out to investors to launch sustainability into the future. “For these companies to move on to the next level and grow, we need the participation of everyone,” Lockwood said. This requires the participation of venture capitalists, corporations, and policy makers.

We are building these world changing technologies by assessing the talent, and fostering an ecosystem that will help these companies through to the end. “As our companies graduate through our program,” Lockwood continued, “we’ve been learning that they are raising a lot of capital and going on to create whole new industries.” Within the next two to three years, many of the companies will raise to series A.

“Our long term vision is to improve human and planetary health by making more industries sustainable,” Lockwood said. The latest solution companies to our portfolio are in cosmetics, construction, fashion, and food industries.

In alliance with SOSV & Mayfield fund, we created the Genesis Consortium, to promote human and planetary health and make it accessible for others to co-invest in a sustainable future. “It’s really important right now that this is a process of collaboration and that we are more inclusive in building ecosystems that gets everyone involved,” Lockwood explained.

Last March we expanded our reach beyond Silicon Valley and opened an office in New York. “When you think of New York, you think of investors, right?” NY Communications Director, Julie Wolf said. Well, while NY pulls in NIH dollars, it’s not so great at pulling in VCs. As of 2016, for every NIH dollar there was only $0.06 in VC. “There’s not a lot of actual biotech startups,” Wolf said. IndieBio wants to change this.

With seven percent of all postdocs moving to New York City, “One of the roles at IndieBio New York is to identify the talent that needs that chance, that opportunity to take their idea and turn it into a company with transformative technology,” Wolf said. “Hopefully we won’t be alone.”

We are entering a new world where we can restore contaminated soil, improve fertility, make new blood supplies, and create abundant supplies of protein. There are solutions to the global challenges, we’re just not pulling our resources together. “We need to recognize that there’s huge potential at our hands,” Lockwood said. “Materials can now be made without extracting more resources from the earth and this is the news we want to focus on.”

This is an opportunity to rematerialize, reimagine, rebuild the world. “We need to stop and listen and reassess how we have been living,” Lockwood said.

For anyone who wants to explore the expansion of biology as a technology, our Managing Director, Po Bronson, along with IndieBio’s founder and Venture Advisor, Arvind Gupta, recently published a roadmap for the curious, Decoding the World.

To learn more about IndieBio and the portfolio of companies, watch our Demo Days. They showcase the talent of scientists who are rebuilding the world.

Introducing IndieBio San Francisco Class 10 and New York Class 1

IndieBio – now operating out of both San Francisco and New York – is proud to announce our new batches of startups. This is New York’s first batch, and San Francisco’s tenth. Though we are running the program virtually for now, all of the startups have secured access to lab and hardware space as needed. The challenge has only increased our focus to make sure these startups’ potentials are not compromised. The familiar feel of communal support and trust is bringing us all together. The transformation from scientists to entrepreneurs has begun and will continue. 

Apply to be a part of the next IndieBio class

Introducing IndieBio SF Class 10

IndieBio SF Batch 10 logos

Asimica

A LEAP FORWARD IN MICROBIAL FERMENTATION 

Biomanufacturing through fermentation is becoming a huge industry, driving growth in foods, materials, fuels, biochemicals, and pharma. One of its biggest challenges is that when microbial factories are maximized for output, the stress causes genetic drift – these are known as “escape mutations.” The microbes’ yield falls, then collapses. Production has to be restarted, and days are lost. First reported in Nature Chemical Biology, Asimica has a novel way to bring stem-like properties to microbes, so that factory cells are continuously refreshed by younger, unmutated microbes. Asimica is selectively choosing fermentation partners to prove their impact.  

https://www.asimica.com/

Advanced Microbubbles

DRUG DELIVERY ACROSS TUMOR AND BRAIN BARRIERS

Getting drugs through the tumor barrier and across the blood brain barrier is a well-known, major challenge for medicine. Advanced Microbubbles uses tiny uniform bubbles, which they agitate with ultrasound at the site of a tumor, to open up the barriers so drugs can enter locally. Their bubbles can be delivered alongside the desired drug, or conjugated to many drugs. 

www.advancedmicrobubbles.com

Carbix

RAPID CO2 SEQUESTRATION / CONCRETE

Carbix turns our built urban world into sinks for CO2. Their novel bioreactor takes enriched CO2 from power and cement plants and in just hours converts it into cement and aggregates for the $900 billion construction industry, and home and yard goods for consumers looking to support the environment with their purchasing power. This technology enables sequestered CO2 to go into long term storage and high-value goods rather than being injected underground. Carbix can sell state and federal carbon credits as a result of their impact on industrial emissions.

http://www.carbixcorp.com

Cybele

NEXT-GEN NATURAL COSMETICS

As people age, their skin stops producing natural moisturizers like hyaluronic acid and ceramides. These tighten the skin, prevent age spots, and retain moisture. Synthetic and animal-based versions are the most common additives to cosmetic products. Cybele has an alternative, natural approach. Their products harness the skin biome, causing it to express these same highly-desired moisturizers, in much higher and efficacious quantities. Beyond moisturizers, they can express natural scents, natural insect repellants, and many more. 

www.cybelemicrobiome.com

Ivy Natal

THE FUTURE OF FERTILITY

Ivy Natal is developing a novel process to create healthy human egg cells from skin cells, giving women the confidence in their ability to choose whether and when to have a child. Many fertility patients cannot have children except through the use of donor eggs. This can be due to surgery, chemotherapy, maternal age, or genetic conditions. Ivy Natal aims to enable these parents to have genetic children for the first time. 

https://www.ivynatal.com/

Khepra

RENEWABLE ENERGY / STORAGE

Khepra is building reactors to harness the stored chemical energy of our common waste streams, such as plastics and biomass. Their reactor uses frictive heating, cavitation, and acoustic pressure to break the chemical bonds in waste with zero extraction. This releases renewable chemicals and fuels. Ultimately they aim to create a two-way market for wastes and renewables. They’ll also partner with wind and solar energy providers to turn excess daytime energy – currently curtailed – into revenue. 

www.khepra.net

Kraken Sense

REAL TIME FOOD & WATER SAFETY

Food and water contamination causes $77 billion in annual economic loss, just in the U.S. Recalls are not only expensive, they inflict real damage to brands’ reputation and scare consumers off entire product sectors. Kraken Sense is bringing real-time testing, with results in two minutes, to automated food and water systems, everywhere from the farms to kitchens. They are making an in-line autonomous device with refillable, single-use cartridges that employ carbon nanotubes magnetized with strain-specific antibodies to measure the concentration of pathogens, not just their presence. The safety of our food system has never been more paramount. 

https://www.krakensense.com/

Liberum

THE DESKTOP PC OF PROTEIN SYNTHESIS

The market size of recombinant proteins today is $119 billion. But it’s expected to reach $400 billion just by 2025. To get there, a better approach to innovation is needed. Today, to produce any sort of custom recombinant protein, it takes weeks. This dramatically slows down scientists’ ability to test, iterate, and improve. Liberum’s affordable, benchtop device will cut that time down to a few hours. Scientists will love the control this gives them over their work. Liberum strongly believes that as custom proteins get as easy as pushing a button, the current $18 billion market for custom proteins will take a larger share of the overall market.
http://www.liberumbio.com/

Microgenesis

FUTURE OF FERTILITY

In a research study, Microgenesis began working with 40 fertility clinics, treating 287 women who had failed all attempts to get pregnant, including at least four expensive IVF treatments. These patients were beyond hope. With Microgenesis’ method of diagnosis and natural treatment, 75% of the women got pregnant. Microgenesis uses microRNA signatures, on swabs from both the gut and fertility biome, to diagnose dysbiosis and treat patients with neutraceuticals and diet-change. They intend to expand through fertility clinics, as well as cultivate a direct-to-consumer brand for women just beginning the journey.  

https://microgenesis.net/

Reazent

AG-TECH

The state of the art in row crops is to reject agrochemicals and employ soil rhizobacteria that support plant growth – known as “PGPRs.” Reazent does it one better. Reazent loads PGPRs into a natural carrier to treat soil, achieving 5x improvement. By improving the plant’s immune system, the crops can also forego pesticides. Reazent can work with up to 116 PGPR strains. Having started in soybeans and peppers, Reazent is now expanding to many crops, testing through both their own trials this summer and with partners. 

www.reazent.com

Spintex

APPAREL / NEXT-GEN SUSTAINABILITY & PERFORMANCE

According to the Sustainable Apparel Coalition, silk has by far the worst environmental impact of any fabric. Innovations over the last century have been few and far between. Spintex has invented an entirely new, scalable method of making silk, inspired by how spiders (rather than silkworms) spin silk. It uses 1000x less energy than plastic fiber formation, and cuts silk emission by half. Spintex matches the material properties of premium silks, with no compromise on look and feel. Already working with several major brands, Spintex will also tune their fibers to improve performance, approaching the rarified properties of spider silk. 

spintex.co.uk


 

Introducing IndieBio NY Class 1:

IndieBio NY is grateful for support from the Partnership for New York City and Empire State Development.

Allied Microbiota

USING MICROBES FOR ENVIRONMENTAL SUSTAINABILITY 

Industrial activity has produced 100 billion tons of contaminated soil in the United States, endangering both human and environmental health. Less than 0.1% of this soil is decontaminated because current technologies don’t work or are too expensive. 

Allied Microbiota’s novel ThermO+ process uses natural processes to destroy toxic organic soil contaminants, including petroleum waste products and chlorinated substances. The process remediates soil in weeks instead of years and is a low-cost method to convert toxic soil to reusable soil. 

http://www.alliedmicrobiota.com/

BioFeyn

NANOCAPSULE-ENHANCED FEED SYSTEMS FOR AQUACULTURE 

Originally developed for human medicine, nanocapsules are tiny molecular transporters that can deliver nutrients, drugs, or natural products to make dramatic improvements in animal health and sustainability. 

On track to outpace capture fisheries by 2030, aquaculture is growing by 15% per year. Yet this growth comes at great cost: many farmed animals die due to overcrowded facilities and disease (in some sub-sectors amounting to 50%), while the environment is polluted with additives and animal waste. 

BioFeyn’s solution is transportable, scalable across species, and integrates into existing supply chains to benefit both people and planet. 

https://biofeyn.com/

Biomage

MAKING SINGLE-CELL SEQUENCING DATA ACCESSIBLE TO RESEARCH BIOLOGISTS 

Single-cell sequencing technologies present a huge opportunity for rapid drug target identification, but data analyses currently require too much time and too many resources for widespread adoption by research teams. Researchers spend 30-fold the amount of time on data analytics as in the wet-lab, which limits discovery to 1-2 drug targets per year. 

The Biomage single-cell platform increases drug target discovery 30-fold at a fraction of the cost, allowing widespread application of cutting-edge sequencing technologies. 

https://biomage.net/

Brightcure

COMBATING UTIs WITH PROBIOTIC PREDATOR BACTERIA 

50% of women and 12% of men suffer from urinary tract infections (UTIs) during their lifetime. Current UTI treatments present problems that include low efficacy, unwanted side effects, and accelerated development of antibiotic-resistant infections. Brightcure is solving the problem of poor treatment options for patients with recurrent UTIs by harnessing healthy, natural bacterial solutions to reduce the overuse of antibiotics. 

bcure.co.uk 

Cayuga Biotech

SUPERIOR TREATMENTS FOR ALL FORMS OF BLEEDING 

Following traumatic injury, the rate of death increases 1% for every 3 minutes a patient continues to bleed. The World Health Organization recognizes that bleeding is a global health threat. Genetic diseases and side effects of prescription drugs (such as anticoagulants) can further predispose individuals to major bleeding events.

Cayuga’s injectable clotting drug targets the site of injury to safely accelerate clot formation and save lives without the risk of thrombosis carried by currently available drugs. 

http://www.cayugabiotech.com/

Halomine

TURNING EVERY SURFACE INTO AN ANTIMICROBIAL SURFACE

Bacteria and viruses move easily surface-to-surface and person-to-person. Surface-associated microorganisms cause one of every three hospital-acquired infections and contribute to COVID-19 transmission.

HaloFilm is a companion product to chlorinated disinfectants that extends the life of chlorine on a surface, providing extended and continuous protection against bacteria and virus transmission, turning every surface into an antimicrobial surface. 

https://www.halomine.com/

Multus Media

ANIMAL-FREE AND SUSTAINABLE CULTURING MEDIA FOR CELLULAR AGRICULTURE AND R&D

Cultivated meat is a sustainable way of producing meat, without the need to kill animals. However, cultivated meat production is very expensive, a product of the animal-based nutrients required for its cultivation: these nutrients currently comprise more than 80% of production costs.

Multus Media is developing tailored, inexpensive nutrients to make cultivated meat completely animal-free and affordable for everyone. 

http://www.multus.co.uk/

Scindo

CONVERTING VINYL PLASTICS INTO HIGH-VALUE COMPOUNDS 

Humans have generated more than 9 billion tons of plastic, and 79% of this has ended up in landfills. Current methodologies are unable to efficiently recycle some of the most commonly produced plastics.

Scindo is creating a novel biological platform for low-energy, green and economical recycling that turns low-value waste products into high-value compounds, creating a viable alternative to landfills. 

https://scindo.bio/

SMT Labs

SCALING AFFORDABLE MOSQUITO BIRTH CONTROL 

Mosquitoes are the most dangerous animal on earth. Mosquito-borne diseases like Dengue, Zika, yellow fever, West Nile fever, and Malaria infect hundreds of millions of people a year. Climate change is causing mosquitoes to spread rapidly, endangering millions more. 

SMT Labs is developing an affordable and scalable mosquito birth control to control the mosquito population and mosquito-borne disease. 

https://smtlabs.co/

Introducing IndieBio New York

The large, systemic problems facing humanity have never been clearer, nor has the need for innovative biotech solutions for these problems. The new IndieBio New York program, launching May 2020, doubles the number of companies building solutions to these problems.

Like the flagship San Francisco program, the companies accelerated in IndieBio New York will address both human and planetary health needs. The IndieBio mission to find startups whose technologies address these problems feels more urgent than ever. The new IndieBio program addresses these problems by providing early-stage biotech startups with three major areas of support as they grow their company:

  • A dedicated team.
  • Research facilities.
  • Mentorship and community.

Meet the IndieBio New York Team

The new IndieBio New York team is excited to welcome the inaugural cohort in May.

Partner, Stephen Chambers, Ph.D

Founding Scientist at Vertex Pharmaceuticals and co-Founder of Abpro Therapeutics.
Former CEO of SynbiCITE, the Innovation and Knowledge Center for Synthetic Biology in the United Kingdom.
Co-Founder of Bio-Start, the United Kingdom’s first life sciences accelerator.

“Working with founders of very early-stage companies, where advising and mentoring and relationship building really affect the life or death of a company, is some of the most rewarding work I’ve done. I look forward to helping founders in our teams move the needle and continue to grow.”


Partner, Rodrigo Mallo Leiva

Founder of 4 companies including a successful exit.
Angel investor.
Managing Director of RebelBio.


Adjunct Partner, Michael Aberman, M.D., M.B.A.

Former President and CEO at Quentis Therapeutics.
Former Senior Vice President of Investor Relations and Strategy at Regeneron Pharmaceuticals.
Executive in Residence at Columbia Technology Ventures.

“IndieBio is known for its broad portfolio of companies across all life sciences disciplines. I’m excited to work with our IndieBio cohorts to develop the next wave of life-changing technologies.”


Communications Director, Julie Wolf, Ph.D.

Former Science Communications for the American Society for Microbiology.
Instructor at the community biology lab Genspace.
Co-Founder of Brooklyn Bio Inc.

“Every founder is not only an advocate for their company, but an advocate for a better future and an advocate for science. We hope that each founder in our program learns to inspire others within the biotech community and beyond.”


Program Manager, Alex Hall-Daniels

Previous Account Executive at Edelman London.
Former Program Associate at RebelBio.

“Our portfolio companies strive to solve major world problems. Working with companies who make crops more drought-resistant, materials more sustainable, and disease vectors less prevalent helps build a better future for everyone.”


Senior Associate, Sheng Ge

Previous Analyst, Associate, and now Senior Associate at SOSV through nearly a decade with the firm.

“I’ve worked with deep tech companies across SOSV and am excited to apply my expertise to the new IndieBio program.”


Program Location

IndieBio New York will be run out of Rockefeller University for its first year, occupying the 16th floor of the Weiss Building. The fully outfitted lab provides researchers with wet lab space, conference rooms, and common spaces for community gathering.

Mentorship and Community

The IndieBio New York program gathers founders of seed-stage companies for a 4-month intensive program. The new program applies the same cornerstone tenets of the San Francisco program: mentorship and community.

Mentors play a vital role in guiding early-stage founders. Throughout the program, mentors share their wisdom through talks to the entire group and by holding office hours for more intimate conversations.

“Relationship building is at the heart of entrepreneurship,” says Managing Director and Partner Steve Chambers. “Knowing whom to approach, and when and how, helps build the strong foundation necessary for companies to flourish. Our mentors serve the founders by sharing relationship-building tips and by becoming a part of the founders’ networks themselves.” The mentor network is further broadened by alliances with the Empire State Development and the Partnership Fund for New York City.

Community also grounds the IndieBio program. Working side-by-side for 4 months, founders learn not only from their mentors but also from each other, forming a support network that endures long after the program ends.

The team, facilities, mentorship, and community are important—and so is program adaptability. The COVID-19 pandemic requires nimble decision making to ensure all 4 components are up to IndieBio standards. Both San Francisco and New York IndieBio teams are working hard to navigate this unprecedented event and innovate program content for the founder communities they serve.

Introducing IndieBio Class Nine

IndieBio helps entrepreneurs build ground-breaking biotech companies. We’re excited to share our ninth class of 11 new startups. They have been here for thirty days, working tirelessly to derisk critical pieces of their science and business. The four month program will culminate in a Demo Day on the 6th of February.

AgriSea is creating methane-negative rice farms in the open ocean, with rice varietals that they’re engineering to grow in saltwater and drought-like conditions. It can also be used for bioremediation of fertilizer runoff zones. Rice feeds half the world, and is a $318 billion market. But in many countries, rice farming is in distress from both drought and seawater flooding. AgriSea’s rice can be grown in open water, or in conventional paddies flooded with seawater. https://www.agrisea.co.uk/

Avisa Myko: The molecule melanin is evolution’s answer to radiation. This natural supermaterial has unparalleled capacity to absorb all of the radiation spectrum and convert it into different forms of energy. Research has long shown that if melanin could be made affordable, there would be wide industrial applications for it — to replace SPF factors to block UV radiation in sunscreens, cosmetics, and clothing, to blocking gamma waves during cancer radiation therapy, and protecting workers and astronauts exposed to gamma radiation. It can also be used in energy applications, such as low-cost batteries and hydrogen production. However, production of melanin industrially has been stymied, and melanin has remained more expensive than gold. Until now. The team at Avisa Myko has spent years reducing the cost of melanin production via fungal fermentation, and can now produce it at 500 times lower than existing methods. Avisa is partnering with many corporations to include their melanin in a variety of products and formulations.  https://www.avisamyko.com/

BioLumen makes a pill for weight loss and gut health; it’s made of a highly functionalized cellulose matrix to entrap sugars in the stomach so they are digested by your microbiome, not your body. https://biolumen.tech/

Chi Botanic: We may not realize how inefficiently many high-value plant products are grown. Some take years, or decades, to grow. And then the desired ingredients are often a tiny part of the plant. Chi Botanic creates just the end products, in bioreactors, without any of the waste — such as aloe, natural rubber, and citrus oils. Plant cells are poised to be the next big market in fermentation. https://www.chibotanic.com/

Dalton Bioanalytics detects thousands of blood biomarkers in a one-shot assay, using liquid chromatography mass-spectrometry enhanced by chemical normalization. https://daltonbioanalytics.com/

Diadem Biotherapeutics makes shelf-stable, engineered exosomes for the anti-inflammatory market, starting with COPD. Their engineered exosomes have the best aspects of both biologics and cell therapies, without their compromises. https://www.diadembio.com/

Lupa Bio: Destructive inflammation underlies the vast majority of chronic diseases, however, current treatments are too toxic to be used in all but the most severe diseases. Lupa Bio is developing an entirely new therapeutic, derived from an oligosaccharide found in human milk, with the potential to be as effective as current drugs yet safe enough for all patients. http://www.lupabio.com/

MemBio makes blood, using a novel hollow-fiber bioreactor to make universal O- blood, replacing or complementing the current volunteer donor system. For hospitals and blood centers, Membio’s OmniBlood solves the shortages in the supply chain and the difficulty of patient matching. http://www.membio.ca/

Michroma is a desperately needed solution for the food tech revolution. Michroma produces natural thermostable colorants for foods and cosmetics that are free of chemicals and mycotoxins. 70% of the foods we eat are colored with dyes. Many are synthetic chemicals linked to hyperactivity and cancer, or extracted from insects. Shouldn’t food dyes be made from food? https://michroma.co/

Pando Nutrition is solving the problem of antibiotic usage in the livestock industry. Even though growth-promoting antibiotics have been banned by the FDA since 2017, they are still widely used throughout the industry. Pando creates super-probiotics for healthy, productive livestock. https://www.pandonutrition.com/

Primitives: Anything made of plastics today can be replaced by biopolymers. Primitives is a biomaterials company that engineers alternative plastics that can sense the environment and communicate to its users. Some applications include compostable food wrap that can tell you when food is rotting, and biodegradable cosmetics that changes color throughout the day. https://primitives.io/

Introducing IndieBio Class Eight

We’re excited to announce our eighth class at IndieBio. IndieBio invests in revolutionary technologies for human and planetary health, and each of these companies, though small today, has tremendous potential to become a very significant and disruptive company. We selected them from well over 300 who applied from all over the world. Over the next four months, they’ll be going through a rigorous process to commercialize their scientific and technical insights.

HUMAN HEALTH 

Beeline

Beeline turns your body’s own cells into drug factories to express antibodies, enzymes, or cytokines. Their method is tissue-specific, facilitating the significant need for localization of drug expression. Their first focus is to replace expensive, monoclonal antibody regimens that have to be injected weekly. They’re working to reprogram patient’s T-regulatory cells to suppress inflammation, effectively curing patients for many years. Rheumatoid arthritis is their first indication.

BiomeSense

The microbiome is one of the most impactful emerging fields in healthcare, yet fundamentally constrained by a lack of biomarkers to measure treatment efficacy. BiomeSense’s platform is a 30x reduction in the cost of doing longitudinal microbiome collection and analysis research, unlocking this exploding market.

Their single-chip, on-toilet design will prep and assay the microbiome strains and upload the data to their cloud. BiomeSense is quickly signing pilot partners to use their device in clinical trials, as well as securing LOIs with partners who desire access to their unique, centralized data. Their platform is well-positioned for CDER Biomarker Qualification for patient monitoring as microbiome therapeutics get approved.

Caspr Bio

Caspr is a diagnostics company that uses CRISPR for rapid detection of antimicrobial resistance.

The World Health Organization considers antimicrobial resistance the number one global health threat. It affects everybody — not just the 700,000 people a year today who die from antimicrobial resistance — but anyone who will develop an infection in the future. Today, when a patient has an infection, it takes three days to determine which bacterial strains are proliferating. Physicians are desperate to know, faster, if a patient has the resistant superbug KPC, or bacteria with the resistant-gene NDM-1. Caspr Bio is making an affordable, point-of-care device that can make this diagnosis in two hours. They use CRISPR to identify the DNA of the most dangerous infectious strains. They will be extending this platform to upgrade many diagnostics with CRISPR.

Gavilan Biodesign

Gavilan Biodesign is an in silico computational design company that redesigns drugs for pharma companies, so cancers cannot develop resistance to the drug.

Cancer cells mutate rapidly. Though targeted therapeutics kill most cancer cells, the mutated ones effectively escape, then proliferate. The cancer comes back. Currently, pharma companies design drugs to target a specific, likely mutation. But then a new mutation makes the cancer resistant to that drug, too. Gavilan is a unique computational drug design company with capabilities new to this field. Their physics-based engine models all possible mutations around a binding site to predict which set of mutations will successfully emerge. Then they redesign a drug to remain effective, not just against one or two mutations, but against all possible future mutations. They can search through 100 trillion molecular structures a day, arriving at superior drug compound structures in a matter of hours. Their goal is to work with many pharma partners to create a new class of targeted therapies that dramatically extend progression-free survival.

Guided Clarity

Guided Clarity has developed a new class of compounds to target and clear cells of dysfunctional mitochondria, improving cellular energy production. Their compounds are synthesized from naturally-occurring ingredients in food, so they are both safe and affordable as a medical food. In their first clinical study on healthy volunteers, the data showed an increase in insulin sensitivity, a reduction in inflammation marker NLR, and improved physical function. Guided Clarity is focused on healthy aging, improving mitochondrial function both in the brain and on the periphery.

PLANETARY HEALTH 

11Biomics

11Biomics has developed a very effective, non-pesticide plant treatment that solves a huge problem for the fast-growing cannabis industry — powdery mildew disease. Powdery mildew disease can spike in a cannabis grow operation overnight, ruining a harvest worth millions. Existing antifungal treatments are ineffective or damage the plant. 11Biomics heals plants in a manner of hours by rebalancing the plant’s phytobiome, using natural hyper-antagonists to fungal diseases. Their platform of seven plant therapeutics allows 11Biomics to tune their therapy to different regions of the country, as well as treat other crops commonly affected by powdery mildew — hops, grapes, and tomatoes.

Blue Planet Ecosystem

Blue Planet develops modular systems that turn sunlight into fish — at an industrial scale.

A Blue Planet Ecosystem is a closed-loop stack of six shipping-containers; the system continuously self-optimizes as algae grows on the sunlight, zooplankton grows on the algae, and high-value commercial fish grows on the zooplankton. Thermal energy management and marine life conversion efficiency is handled by their software. In locations where land is cheap and sunlight is plentiful, dozens or hundreds of stacks can be deployed by customers. These will be countries, infrastructure investors, foodservice operators, farmers, and land-developers with temporarily-unused properties. Though fish is the output, the economics are very distinct from aquaculture because it’s a zero input system, creating a new asset type for agri-franchisers.

Decomer Technology

Plastics pollution is an exploding issue for CPG brands as the environmental impacts of products designed to be used for minutes but last for lifetimes is seen. Rather than attempt to change mass-market consumer behavior, industry is challenged to think green while maintaining convenience.

To solve this, Decomer Technology has developed a new sustainable packaging material that is edible and rapidly dissolves in liquids. It has widespread uses across the food industry, pharmaceuticals, agriculture, and detergents. Their material is odorless, tasteless, and hypoallergenic, though flavors and micronutrients can be added. It can be tuned to dissolve in cold water, or hot water, or both. It’s very low cost and scalable for high volume manufacturing uses. They are partnering with CPGs for testing.

Electro-Active Technologies

Around the world, biomass is inefficiently converted to biogas or syngas, then to useable electricity. A more efficient approach is to convert liquid biomass and food waste straight to hydrogen for fuel cells. The founders of ElectroActive developed this bioconversion technology at the Oak Ridge National Laboratory in Tennessee. Their modular power cubes will be used in any quantity to provide renewable power anywhere food waste or biomass is prevalent. Electro-Active is a scalable solution that serves many industrial supply chains, especially in municipalities that have banned food waste from landfills.

New Culture

New Culture is making cheese without the cow. Combining dairy proteins, expressed by microflora, with plant lipids and sugars, their method arrives at curds that are then advanced into the traditional cheesemaking process, be that stirred, kneaded, stretched or aged. New Culture’s cheese has the signature textural properties and qualities that we’re all familiar with in dairy cheese. By removing the cow from the cheesemaking process, New Culture’s cheese is more sustainable, ethical, and better for the world.

Tinctorium

Tinctorium is making the greenest bluejeans for the planet, using biofermentation in their indigo dye process. Across the $100 billion jeans market today, the vast majority of blue denim relies on chemical synthesis and chemical reduction, which significantly harms both the environment and the health of denim workers. Even naturally-grown, plant indigo is reduced with corrosive chemicals. Tinctorium is unique among denim producers, as their system is both scalable and free of chemical synthesis and reduction.

  

Check out our events for opportunities to meet the founders and learn about the future of biotech, and mark your calendar for Demo Day on June 25th!

About IndieBio

IndieBio is the world’s leading life sciences accelerator, having funded 105 biotech startups since starting in March 2015. Companies from all over the world apply to be part of a 4 month acceleration program which includes $250,000 funding, dedicated mentorship, and 24/7 access to a co-working space and bio-safety level 1 & 2 labs. During the program, teams are focused on turning science into product, closing customers, and raising follow-on investment.

Apply here to be in our next class!

Introducing IndieBio Class Seven

At IndieBio, we are on a mission to turn scientists into entrepreneurs to solve the world’s biggest challenges. Biology as a technology has now come to the point where we are able to design the world around us with unprecedented speed and precision to improve planetary and human health.

This renaissance is being fueled by converging megatrends of machine learning, CRISPR, genomics, and cellular agriculture and a wave of forward-thinking scientists leaving the halls of academia to build startups.

We have made many improvements to the IndieBio program in the past several months, including the addition of a leadership track with tailored mentors and sessions to help scientists become leaders.

We’ve also introduced an Adjunct Partner board, composed of subject-matter experts across the life sciences. The first six members are:

  • Alexander (Sasha) Kamb, PhD: Sasha has decades of experience leading R&D teams in biopharma. He’s currently the CSO of A2 Biotherapeutics, and previously was Senior VP of R&D at Amgen.
  • Darrin Crisitello, MBA: Darrin brings years of sales experience from across healthcare. He has scaled multiple large sales teams, with his most recent being Color Genomics and Natera.
  • David Eagleman, PhD: David is a renowned neuroscientist, entrepreneur, and author. He’s the CEO of NeoSensory, an adjunct professor at Stanford University, writer and presenter of PBS’s The Brain, and advisor to several companies and non-profits.
  • Leonardo Teixeira, PhD: Leo embodies the scientist to entrepreneur story of many IndieBio founders. He co-founded GeneWeave coming out of his PhD at Cornell, which was later acquired by Roche.
  • Shehnaaz Suliman, MD, MPhil, MBA: Shehnaaz brings a wealth of experience at the intersections of medicine and biopharma. She has a deep expertise in strategy and corporate development, and was also a practicing physician.
  • Tim Lu, MD, PhD: Tim is a pioneer in synthetic biology, weaving together a background in medicine, biomedical engineering, and computer science. He’s an assistant professor at MIT and serial entrepreneur, with his latest venture being Senti Biosciences.

Today we’re excited to announce our seventh class at IndieBio. Founders have converged on San Francisco for the next four months to productize their insights through a design driven process. Startups span the future of food, consumer biology, therapeutics, and diagnostics.

BioRosa

BioROSA enables early detection and improvements in the pediatric diagnostic process for autism by providing clinicians validated blood tests to improve diagnostic certainty.

Chronus Health

Chronus Health is building a handheld diagnostic device that reduces turnaround times at clinics from days to minutes. Their initial launch for CBC and CMP tests account for 50% of all blood tests performed.

Clinicai

Clinicai is building a smart toilet monitor for non-invasive early detection of gastrointestinal cancers and diseases.

Convalesce

Convalesce is creating stem cell therapies for neurodegenerative diseases, starting with Parkinson’s. With a proprietary biomaterial they create a brainlike micro-environment suited for stem cell differentiation.

Filtricine

Filtricine is developing a drug-free nutrient deprivation therapy to exploit metabolic dependencies to kill cancer cells.

Oralta

Oralta designs tailored probiotics for oral health. Their probiotics balance communities of microbes to treat bad breath, tooth decay, and gum disease.

New Age Meats

New Age Meats is making clean meat with an automated data-driven platform.

NovoNutrients

NovoNutrients makes food from CO2. Their microbes break down industrial emissions of carbon dioxide and reassemble them into low-cost and nutrient-rich aquaculture feed and specialty ingredients.

Ember

Ember is a distributed platform to bring emergency medicine out of the hospital. By connecting patients in need to health professionals in the community, they speed up response times and improve outcomes.

Quartolio

Quartolio is a knowledge management platform that accelerates research by connecting the dots across scientific articles, clinical trials, and patents with the power of NLP.

Serenity Bioworks

Serenity Bioworks is developing an immune tolerance platform for biologics. Their first product will unlock redosable gene therapy for Hemophilia.

Stämm

Stämm is reinventing the infrastructure of bio-manufacturing with a new approach to fermentation. Their miniaturized bioreactors accelerate condition optimization, lower cost, and allow for modular scaling.

Check out our events for opportunities to meet the founders and learn about the future of biotech, and mark your calendar for Demo Day on November 6th!

About IndieBio

IndieBio is the world’s leading life sciences accelerator, having funded 94 biotech startups since starting in March 2015. Companies from all over the world apply to be part of a 4 month acceleration program which includes $250,000 funding, dedicated mentorship, and 24/7 access to a co-working space and bio-safety level 1 & 2 labs. During the program, teams are focused on turning science into product, closing customers, and raising follow-on investment.

Apply here to be in our next class!

Introducing IndieBio Class Six

Today we’re extremely excited to announce the fourteen startups joining IndieBio Class Six in downtown San Francisco.

At IndieBio, we are on a mission to solve the world’s biggest and toughest problems by using biology as a technology. We are giving scientists the resources they need to drive innovations across food, biopharma and healthcare, agtech, regenerative medicine, neurotech, biomaterials and beyond.

When we first introduced the first class in 2015, we made a bet that scientists are more creative, driven and entrepreneurial than most VCs give them credit for. IndieBio was built on the belief that with the right environment and structure, scientists can make the shift to entrepreneur and build transformational companies. Three years later, we are amazed at the results: we’ve had the privilege of working with 81 of of the most exciting founders in the world and playing a role in their growth – including Memphis Meats (cultured meat), Koniku (biological neurochips), SyntheX Therapeutics (targeted therapeutics), Catalog (biological data archiving), Ava Winery (engineered wine) and Qidni Labs (implantable artificial kidneys). We are proud to have created a repeatable design-driven process to enable scientists productize their discovery.

Class Six is comprised of therapeutics, cell therapies, food & agriculture and diagnostics for cancer and neurological disease hailing from all over the world. More than ever, the IndieBio teams are on the cutting edge of science and solving massive problems in the world today.

Check out our events and make sure to RSVP for Demo Day, which is happening on April 17th at the Herbst Theatre.

Antibiotic Adjuvant

Delivering AI-powered decision support software designed to monitor and reduce antibiotic resistance.

BeeFlow

Developing smart and strong bees for crop pollination. With their technologies, farmers can increase crop yields up to 90%, target specific crops for pollination, and substantially reduce bee population decline.

Dahlia Biosciences

Leading the next generation of multiplexed in situ single-cell RNA analysis tools for research and diagnostic applications.

Jointech Labs

Pioneering access to high quality fat grafts, fat-derived stem cells and cell therapies. Their device enables doctors, clinics and hospitals to provide safe and cost-effective non-surgical treatments for patients.

Lingrove

Creating ‘wood’ without the tree. Their formable, natural fiber and resin replicates the performance, look, feel and re-usability of premium wood from scalable, carbon negative materials.

MezoMax

MezoMax enables faster bone fracture healing, improved osteoporosis treatment, and stronger bones in elderly patients with their novel calcium gluconate stereoisomer, which regulates calcium and mineral metabolism.

Neurocarrus

Developing long acting non-opioid chronic pain medications. Its novel delivery system eliminates addiction potential and side effects that are seen across all opioids.

Nivien Therapeutics

Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies. Their compounds overcome multiple resistance mechanisms across 15 cancers to increase efficacy and decrease toxicity of treatments.

Nuro

Nuro enables instant communication and computing for millions of incapacitated patients in ​post-surgeries and ICUs, ​nursing homes and rehabilitation​​ by using brain signals.

Onconetics Pharmaceuticals

Onconetics Pharmaceuticals develops gene therapies which target tumor cells with specific gene expression profiles. The effector arm of the therapy involves a genetic switch which activates an apoptotic inducer to kill the cancer cell and spares healthy tissue.

sRNAlytics

sRNAlytics has developed a novel bioinformatics platform to identify error-free, small RNA biomarkers. Their Proof-of-Concept work in Huntington’s Disease validated eight biomarkers that are 100% accurate for classifying early vs. late stage disease, and disease progression.

Sun Genomics

Sun Genomics is a microbiome health company focused on curing dysbiosis through personalized probiotics. Their platform enables the highest resolution profiling of customer gut makeup, empowering them to make and track changes over time.

Terramino Foods

Terramino Foods is reimagining seafood, using fungi and algae to make healthy, affordable, and toxin-free products.

Vetherapy

Vetherapy creates novel stem cell therapies for cats, dogs, and horses.  Their most innovative product speeds up wound healing and treats autoimmune and inflammatory diseases.

Announcing IndieBio Summer 2017 Class!

IndieBio is incredibly excited to announce our fifth class of life science companies. Founders have come to San Francisco from all over the world, including Chile, South Africa, Canada, and across the USA.

These teams are tackling problems in a host of industries such as gene therapy, regenerative medicine, the future of food, and Health IT.

BioAesthetics

BioAesthetics is regenerating the nipple-areolar complex for the 200,000+ women whom undergo mastectomies every year.

DNAlite

DNALite Therapeutics is developing gene therapy treatments for the gastrointestinal tract. The first lead candidate is for colon cancer, which is the second deadliest cancer in the U.S.

Finless Foods

Finless Foods is producing real fish meat in vitro to feed 8B+ people in 2020. Their fish is free from the mercury, plastic, and hormones that come with all aquaculture and factory fish.

Health Linkages

Health Linkages is the Data Provenance Company. Health Linkages uses a combination of blockchain and big data to enable healthcare and life science institutions to trust, protect and share their data.

QuantumCyte

QuantumCyte is enabling a deeper understanding of the immune system and cancer biology by enabling next-gen single cell analysis. Their technology has unprecedented ability to analyze large numbers of cells at industry leading resolution.

Pheronym

Pheronym is creating an all natural highly effective insect control for agriculture. By leveraging pheromone spray they double nematode’s effectiveness as an organic insecticide to rival chemicals, without any of the negative health or environmental impact.

Prellis Biologics

Prellis is creating living tissues and organs for pharmaceutical testing and organ transplant. Prellis instantaneously prints high resolution tissue scaffolds that grow into functioning human organs.

Proteorex Therapeutics

Proteorex is discovering small-molecule drugs to treat diseases with the greatest unmet medical need. Their platform can rapidly and cost-effectively unlock previously undruggable targets and has produced multiple partnered compounds.

Stelvio Oncology

Stelvio is focused on delivering precision medicine diagnostics and novel therapeutics for glioblastoma. The resistance of high-grade glioma to conventional cytotoxic drugs has prompted our development of a novel approach to therapy, including differentiating glioma stem cells to less tumorigenic cell fates.

Sugarlogix

Sugarlogix is creating sugars with functional benefits for healthier foods. Their functional sugars enhance the immune system, promote gut health, and reduce inflammation without compromising taste.

TheNotCo

NotCo is combining AI with food-science to craft cutting-edge plant-based foods that deliver unprecedented experiences: Greek Yogurt, Milk, Cheese, Mayo all tasting like the real thing (and even better).

UBA Biologix

UBA cleans industrial wastewater from coal, gold, and platinum mines with an organic bioremediation system. Their first system is operating on a large coal mine in South Africa.

About IndieBio

IndieBio is the world’s largest life sciences accelerator, having funded 67 biotech startups since starting in March 2015. Companies from all over the world apply to be part of a 4 month acceleration program which includes $250,000 funding, dedicated mentorship, and 24/7 access to a co-working space and bio-safety level 1 & 2 labs. During the program, teams are focused on turning science into product, closing customers, and raising follow-on investment.

With a focus on biology as a technology, IndieBio companies solve problems in a huge range of industries such as the future of food, biopharma and healthcare, agtech, regenerative medicine, neurotech, biomaterials, and more. Notable alum include Memphis Meats, Koniku, SyntheX Therapeutics, Catalog, Ava Winery, and Qidni Labs.

Apply here to be in our next class!

Announcing IndieBio’s 4th Class!

IndieBio's 4th Class
IndieBio's 4th Class

IndieBio is excited to announce our newest class of thirteen biotech startups. These companies are bringing innovation to a host of industries, from classical biotech spaces like drug development and medical devices all the way to veterinary, information storage, and utilities markets.

While these companies will be based in downtown San Francisco for the next four months, all their technologies will have global impact.

A2a

A2A Pharmaceuticals designs computationally pre-optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections.

Animal Microbiome

Animal Microbiome helps the monitoring and treatment of chronic health conditions in animals by providing a novel microbiome testing service.

BioInspira

BioInspira has developed a virus-based sensor network which will enable detection of airborne chemicals remotely and in real time, creating the next generation of infrastructure for industry.

Catalog

Catalog is harnessing DNA to store the world’s information.

DxRx

DxRx is a scalable digital health medical practice treating early stage alcohol addiction through telemedicine and behavior modification.

GEA Enzymes

GEA Enzymes creates designer proteins by finding and manipulating specific enzyme activity. They make enzymes for the food industry that reduce saturated fat levels while maintaining consistent aroma, taste, and feel.

Mendel Health

Mendel Health automates matching cancer patients to clinical trials through personal medical history and genetic analysis.

NeuroQore

NeuroQore is commercializing an innovative new repetitive transcranial magnetic stimulation (rTMS) therapy system for treatment of depression and a range of other psychiatric and neurological disorders. rTMS is an emerging therapeutic brain stimulation technique that does not require anesthesia.

Pure Cultures

Pure Cultures develops and manufactures novel prebiotics and probiotics to support the health of animals and reduce antibiotics in our food chain.

Ravata Solutions

Ravata Solutions is transforming transgenic model development through automation with an aim of increasing pre-clinical medical discovery and innovation by 10–100x.

Scaled Biolabs

Scaled Biolabs is accelerating biologic, gene, and cell therapies using smart microfluidic chips. Thousands of cell experiments can be parallelized and automated on their lab-on-a-chip system, increasing throughput, precision, economy, and insight that can lead to dramatic innovations in organogenesis, fermentation condition optimization and therapeutic production.

Venomyx

Venomyx is bringing antivenom into the 21st century with the world’s first toxin-specific snake antivenom. Their solution will make antivenom treatment safe, effective, and affordable for the millions of snakebite victims per year around the world that are currently underserved.

ViaeX

ViaeX creates biological nanofiltration systems for water and air which are 400% more efficient than current solutions and enable selective pollutant and bacteria targeting. These systems are biodegradable, low cost, and rapidly scalable to enable fast deployment in cities around the world facing serious pollution issues.

IndieBio’s 15 Latest Biotech Startups

IndieBio’s 15 Latest Biotech Startups
IndieBio’s 15 Latest Biotech Startups

Today, we stand on the brink of the fourth industrial revolution which fuses the physical, digital and biological spheres of technology that will fundamentally alter the way we all treat our health, eat sustainable and live better. This revolution which is being built by hundreds of startups around the world will have a biological base.

IndieBio is pleased to announce the latest 15 IndieBio companies based here in San Francisco. Based in SF, they all have a global vision, hailing from all corners of the globe to change humanity through a blend of technology and biology. In alphabetic order:

Amaryllis Nucleics

Amaryllis empowers researchers by accelerating important discoveries in genomics. Our technology halves the time and reduces the cost of RNA sequencing by 8-fold to empower the cutting edge cancer diagnostics, pharmaceutical development, and food security innovations.

Ardra

Natural and petroleum free products are the fastest growing category in cosmetics, worth over $23B globally. Ardra is engineering technologies to produce completely petroleum-free, high purity, and sustainable biochemicals for the cosmetics market, as well as for pharmaceuticals and foods.

AstRoNA

Food poisoning is a serious global concern today with over 1 in 6 people getting food poisoning resulting in over 128,000 hospitalizations in just the US every year. AstRoNA Biotechnologies is engineering a simple to use detector that can be deployed on-site at every phase of food production from field to table. Our technology can screen all food types in under an hour versus today’s 48 hour standard food safety process.

BioNascent

BioNascent is determined to close the gap between the health outcomes of breastfed and formula fed infants. To do so, we manufacture the world’s first humanized infant formula aimed at delivering a perfect balance of essential amino acids and carbohydrates.

Endura Bio

Twenty five percent of the world’s arable land is currently unusable due salt groundwater contamination and more arid environments. Endura Bio is engineering salt and drought tolerant plants to be more salt and drought tolerant to increase yields from marginal lands globally, unlocking the potential to feed the world.

Genome Surveillance

DNA sequencing is driving the new genomic revolution but it’s currently bottlenecked with high compute costs and inaccuracies. Genome Surveillance is revolutionizing DNA sequencing to make it ten times faster and more accurate through reducing the heavy computational load and dropping it to a fraction of the cost of current technologies.

Jungla

Today we only understand what ~0.5% of the genetic variants in patient genomes mean and it impedes our ability to diagnose and treat genetics diseases and risk factors. At Jungla, we have developed a software platform that can accurately model the impacts of mutations and accelerate diagnostic development by 5x by harnessing advanced statistical algorithms that were developed at the leading Stanford bioinformatics lab.

Knox

Knox Medical Diagnostics is bringing hospital level asthma management technology to families at home with the first tool to revolutionize decades old practices. Like a blood sugar monitor for diabetes, this tool provides predictive insights to parents of asthmatics that will prevent asthma attacks, enable proactive medication management, and give patients and parents peace of mind.

mFluidX

Zika Virus, Dengue Fever, and other global pandemics ravish countries as a result of a lack of rapidly deployable field based diagnostics. mFluidX has created a DNA diagnostic test the size of a stick of gum that can be deployed and provide results in 30 minutes. All with a self-powered disposable chip that costs 1000x less than current bulky benchtop based lab diagnostics.

MiraculeX

MiraculeX is creating the next generation of the best tasting and healthy sweeteners in the world using plant proteins under one calorie per serving. We get rid of the sugar and terrible aftertaste of your everyday sweeteners.

MycoWorks

MycoWorks is building a world with fewer plastics, no toxins, and zero waste by harnessing the power of Mushrooms. We grow natural alternatives to plastic foams, textiles, and leather, for use in aerospace, automobiles, apparel, and architectural interiors.

OneSkin

Safety testing for cosmetics today relies on inaccurate and inhumane animal testing. OneSkin is developing a human 3D skin tissue model to do toxicity tests that are more accurate, reliable, and completely animal free that can provide a deeper understanding of human skin.

Qidni

Over one million people globally die of untreated kidney failure each year. In addition, dialysis technology has stagnated over the last fifty years with virtually no progress. Qidni Labs is building an implantable artificial kidney for 10% of patients with kidney disease, many of which get kidney failure. Our device is estimated to last the equivalent amount of time as a transplanted kidney without needing maintenance or cleaning.

SyntheX

SyntheX is expanding drug design into the ‘undruggable’ space for the treatment of cancer and rare diseases. We implement an innovative platform for the accelerated discovery of new classes of therapeutics that target the Achilles’ heel of cancer cells in a highly specific and selective manner.

Willow Cup

Willow Cup is optimizing plant-based proteins to create healthy animal-free options for premium indulgences, starting with specialty tea and coffee. We are hacking the infinite properties of plant proteins to replace traditional dairy for a more sustainable future.

Biology is Technology.

IndieBio SF, Announces First Class of 11 Biotech Startups

IndieBio's First class
IndieBio's First class

There is a major funding gap for very early stage bio-entrepreneurs. Backed by SOSventures, a $200million dollar VC fund, IndieBio is the world’s first accelerator dedicated to early stage biology startups.

We’re offering a total package of $100k, including $50k in cash, IndieBio, a dedicated biolab in San Francisco, brings together the world’s leading scientists and entrepreneurs to revolutionize the way biotech is done.  Startups receive free access for one year and a tailored program that helps scientists become experienced bio-entrepreneurs.  The 100-day program culminates in a demo day where the teams present to VCs and press the science and business of the company.

IndieBio is excited to announce its first batch in San Francisco kicking off on February 28.

Indie Bio SF: Session I—Spring 2015 (SI)

Pembient

Eliminating the $750 million illegal rhino horn poaching trade by growing rhino horns made from rhino DNA and 3D printed keratin.

Extem.co

Enabling a thousand fold increase multipotent stem cell production over the industry standard, enabling a stable supply chain for regenerative medicine and basic research.

Orphidia

Creating a ten dollar real time blood diagnostics “lab on a chip” that can test for up to 50 diseases with one drop of blood, enabling field based, portable diagnostics anywhere in the world.

Affinity

Enabling a 10-fold increase in yield for human bio-therapeutic antibodies used in the current $45B bio-therapeutics market.

Clara Foods

Producing ex-vivo egg whites that eliminate the current inefficient and inhumane paradigm of the egg battery farm industry, supplying the growing egg white market with a humane and less expensive alternative.

aBioBot

Integrating machine learning and computer vision for lab robots that will enable next generation scalable automation tools to triple the output of the $23B R&D industry.

Blue Turtle

A bioengineered probiotics therapeutics platform that enables the creation of “enzyme factories” in patients’ gut microbiome to treat diseases from protein deficiencies and result in treatments that are 100x less expensive than current therapies.

Bioloop

Bioengineereed textiles that eliminate the need for harvesting cotton, enabling fully customizable fabrics for the multi-billion dollar fashion and industrial textiles industries.

Arcturus Biocloud

Bringing a cloud-based science platform to education, makers, and non-scientists.

Sensa.io

Open source bioreactors for every home, lab, and school.

Ranomics

Developing a first-in-class rare genomic variation database to give clear functional implications for human genome sequencing results.

About SOSventures

We are a collaborative team of engineers, designers, mentors, problem solvers, inventors, technology pioneers, entrepreneurs, and founders of global organizations. We are dedicated to our entrepreneurs and their vision of bettering the world.

For more information, please visit www.sosventures.com

About IndieBio

IndieBio is short for Independent Biology, a new way for scientists, entrepreneurs, and tinkerers to shape their own destiny and make something that matters. At IndieBio, we provide seed funding and intensive mentorship to drive this transition in only three months and launch our graduate companies into the world of biotechnology to make their fortune.

For more information, please visit www.indie.bio

What next?

We received an incredible number of great applications from across the world (more information to come in the next couple of weeks) but we have also just started sending out our rejection emails as well for the first application cycle and for some of you reading this, we’ll have attached a link to this post to discuss some of the reasons why your team submission might not have been successful in this application cycle.

What if you didn’t get into the first Indie.Bio class?

Rejection is part of the process of building any company, from the day your idea is born, you have to nurture it through the objections of friends, family, co-founders, potential customers and investors. For many of you this isn’t the end, it’s just the beginning of your journey and for some of you not successful in this cycle, we encourage you to apply with new ideas and projects as well as refined projects that you’d previously applied with, we’ll be opening up applications for fall 2015 in SF and Cork applications are open now for the Summer.

So what are we typically looking for in our applications?

1. Team: Strong, dedicated team with at least two full time co-founders (or at least willing to go full time upon funding).
2. Strong science: based on your own experiments, alpha/beta products or current literature, is your science likely to work?
3. Coming to San Francisco: Is your team willing to relocate to the San Francisco Bay area for the 100 day program (at least)?
4. 100 Days: Will you be able to develop a product or service within the 100 days of the program? How will you show investors during and after demo day that you’re ready for the next round of investment to scale your company?
5. Vision & Market potential: What’s the grand vision for your company? How will your technology meaningfully help humanity? Is this more than a small service or product and does your company have the potential to build a $100m-$1BLN+ biotech business in 5-10 years if you’re successful?

Some of the applications we received were VERY interesting scientifically but needed just a little more work to show that the science might actually work, in those cases we’d highly recommend joining your local biohacker space or local lab and continuing your work and applying for the next cycle.

Just remember as Carl Sagan once wrote “Somewhere, something incredible is waiting to be known.”

Ideating in Biotech: Request for Startups

Ideating in Biotech: Request for Startups
Ideating in Biotech: Request for Startups

With the recent announcement of the launch of Indie Bio (our new idea stage biotech accelerator launching in downtown San Francisco this Jan and in Cork in the summer) and the addition of the Berkeley Biolabs team, we thought it was time to send out a request for startups, not just any startups, idea stage biotech startups, for those who want to build biotechnology from the ground up, with access to funding, a biosafety level 2 (BSL2) molecular biology lab and world class list of scientific and business mentors.

We’ve pulled together a wishlist of SynBio and classical biotech idea areas we’d love to have application in but we aren’t limiting, as novel applications of biology are limited only by your imagination.

Our first class of 10 funded startups, starts at the end of Jan 2015 and we’d really love for any and all innovators to apply!

So who should applyAnyone, if you have an idea that you’ve been dying to develop in biotech, synthetic biology or any new or unusual form of programming life, send in a short application (it should only take you 30 mins) and please feel free to send in multiple applications for multiple ideas.

Whether you’re an undergrad, PhD student, PostDoc, Professor, Industry Professional or just a citizen scientist who’s passionate about biology, we’d love to hear from you and we’d welcome an application or multiple for your idea stage biotech startup.

So with that, let’s start with the idea gasoline (hopefully biodiesel of course!) Here are a few ideas we’d like to invite to send in an application but there are ALOT more!

Request for Startups:

Food tech

Replacing any animal or plant enzymes, protein, expensive flavorings or processes that can be made for a fraction of the cost in other cellular systems (or other plants). Think Vegan Cheese, In vitro meats and Eggs! GMO’s welcomed!

Industrial

Utilizing biological processes to solve industrial challenges and production, everything from industrial enzymes through to accelerating production of raw materials and proteins (Novozymes is a good example)

Bioremediation

Utilizing plants, fungi and bacteria to clean up environmental contamination, including water filtration, land decontamination, Carbon capture and radioactive cleanup

Biomining

Use of plants, fungi or bacteria that can be used to extract metals from the environment in a non destructive and efficient manner

Biomedical applications

Diagnostics, therapeutic development platforms and therapeutics (ideally in orphan diseases)

Cybernetics

True melding of human biology and machines, think grinders and not quantified self.

Biomaterials

Novel biomaterials made with phage, viruses, bacteria, fungi, animal cells or plants. From wearable biomaterials to construction biomaterials

Bioenergy

Storage and generation of biological power based systems

Biological computation

Novel computational systems built with biology, i.e. biomolecular logic is just the start

Biosensors

Detecting substances in the environment with bacterial sensors

Space biotech

Novel applications of biology to make life possible/easier for space travel and long term survival off world

Consumer Biotech

Any product or service, made with novel biology that can be sold direct to consumer, glowing plants, Civet Coffee and color changing flowers are only the start!

Tissue Engineering

From human tissue replacement, 3D Bioprinting to building human organs and beyond

Reproductive Biotech

Think about artificial wombs and beyond!

Neurocognitive Tech (NeuroTech)

Any technology that helps us visualize and understand the brain and its neuronal outputs and action that understanding.

Quantum Biology

The migratory Robin sees the the earth’s magnetic field through quantum biology, some enzymes work on quantum principles and chloroplasts improve sun harness efficiency through quantum effects. We’d love to fund product ideas in this space.

And remember, don’t forget to APPLY with your idea stage biotech. We are funding innovation!